Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05727904 |
Recruitment Status :
Recruiting
First Posted : February 14, 2023
Last Update Posted : April 30, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Melanoma Unresectable Melanoma Melanoma | Biological: Lifileucel plus Pembrolizumab Biological: Pembrolizumab with Optional Crossover Period | Phase 3 |
Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial. More info ...
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 670 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma |
Actual Study Start Date : | March 30, 2023 |
Estimated Primary Completion Date : | March 1, 2028 |
Estimated Study Completion Date : | March 1, 2030 |
Arm | Intervention/treatment |
---|---|
Experimental: Arm A
Lifileucel plus Pembrolizumab
|
Biological: Lifileucel plus Pembrolizumab
A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive Pembrolizumab followed by the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. Patients will then continue to receive Pembrolizumab every 6 weeks until disease progression.
Other Names:
|
Active Comparator: Arm B
Pembrolizumab alone with Optional Crossover Period
|
Biological: Pembrolizumab with Optional Crossover Period
Patient will receive Pembrolizumab monotherapy every 6 weeks until disease progression. Upon verified confirmed disease progression by the blinded independent review central committee, patients may proceed to lifileucel monotherapy during an optional crossover period if they meet eligibility criteria. Optional crossover: A tumor sample is resected from each patient for Lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of non-myeloablative lymphodepletion, lifileucel infusion followed by IL-2. |
- Objective Response Rate and Progression Free Survival [ Time Frame: 5 years total duration ]To compare the efficacy of lifileucel plus pembrolizumab with the efficacy of pembrolizumab alone measured by objective response rate (ORR) and progression-free survival (PFS) assessed by the blinded independent review committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Overall Survival [ Time Frame: 7 years total duration ]To compare the efficacy of lifileucel plus pembrolizumab with the efficacy of pembrolizumab alone measured by overall survival (OS)
- Complete Response Rate, Duration of Response and Event Free Survival [ Time Frame: 5 years total duration ]To compare the efficacy of lifileucel plus pembrolizumab with the efficacy of pembrolizumab alone measured by complete response (CR) rate and duration of response (DOR) and event- free survival (EFS) assessed by the BIRC per RECIST v1.1
- Objective Response Rate, Progression Free Survival, Complete Response Rate, Duration of Responses, Event Free Survival and PFS2 [ Time Frame: 5 years total duration ]To compare the efficacy of lifileucel plus pembrolizumab with the efficacy of pembrolizumab alone measured by ORR, PFS, CR rate, DOR, and EFS assessed by the investigator per RECIST v1.1 and PFS2 assessed by the investigator
- Adverse Events [ Time Frame: 5 years total duration ]To characterize the safety and tolerability profile of lifileucel plus pembrolizumab and pembrolizumab alone in participants with unresectable or metastatic melanoma
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant has a histologically or pathologically confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma.
- In the investigator's assessment, the participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and an estimated life expectancy of > 6 months.
- Participant is assessed as having at least one resectable lesion (or aggregate lesions) for lifileucel generation.
- Participant must have at least one measurable disease as defined by RECIST 1.1 following tumor resection.
- Participants must have adequate organ function.
- Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control.
- Participants who are > 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor.
Exclusion Criteria:
- Participant has melanoma of uveal/ocular origin.
- Participant has symptomatic untreated brain metastases.
- Participant received more than 1 prior line of therapy.
- Participant received prior therapy for metastatic disease
- Participants with a BRAF V600 mutation-positive tumor received prior adjuvant/neoadjuvant ICI therapy only
- Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation, such as systemic infections; seizure disorders; coagulation disorders; or other active major medical illnesses of the cardiovascular, respiratory, or immune systems.
- Participant has any form of primary or acquired immunodeficiency (eg, SCID or AIDS).
- Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or were curatively treated >1 year ago, and in the judgment of the investigator do not pose a significant risk of recurrence.)
- Participant has a history of allogeneic cell or organ transplant.
Other protocol defined inclusion/exclusion criteria could apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05727904
Contact: Iovance Biotherapeutics https://www.tilvance-301.com | 1-844-845-4682 | Clinical.Inquiries@iovance.com | |
Contact: Iovance Biotherapeutics Study Team | 1-844-845-4682 | Clinical.Inquiries@iovance.com |
Study Director: | Iovance Biotherapeutics Study Team | Iovance Biotherapeutics |
Responsible Party: | Iovance Biotherapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT05727904 |
Other Study ID Numbers: |
IOV-MEL-301 TILVANCE-301 ( Other Identifier: Iovance Biotherapeutics, Inc. ) TILVANCE ( Other Identifier: Iovance Biotherapeutics, Inc. ) |
First Posted: | February 14, 2023 Key Record Dates |
Last Update Posted: | April 30, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Tumor Infiltrating Lymphocytes TIL Metastatic Melanoma Unresectable Melanoma Cell Therapy Cellular Immuno-therapy IL-2 Non-myeloablative lymphodepletion (NMALD) Check point inhibitor Melanoma Lifileucel Stage III Melanoma Stage IV Melanoma Skin cancer Skin cancer types |
Malignant melanoma Autologous Adoptive Cell Therapy Autologous Adoptive Cell Transfer LN-144 Pembrolizumab Pembro Adjuvant/Neo-adjuvant BRAF/MEK ICI BRAF v600 Immune checkpoint inhibitor Tumor infiltrating T-cells TILVANCE TILVANCE-301 |
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |
Skin Neoplasms Neoplasms by Site Skin Diseases Pembrolizumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |